DekaBank Deutsche Girozentrale cut its position in Allergan PLC. (NYSE:AGN) by 0.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 167,258 shares of the company’s stock after selling 1,203 shares during the quarter. DekaBank Deutsche Girozentrale owned about 0.05% of Allergan PLC. worth $38,410,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Honeywell International Inc. lifted its stake in Allergan PLC. by 13.6% in the 2nd quarter. Honeywell International Inc. now owns 168,130 shares of the company’s stock worth $40,871,000 after purchasing an additional 20,100 shares in the last quarter. Israel Discount Bank of New York purchased a new stake in Allergan PLC. in the 1st quarter worth approximately $988,000. Sumitomo Life Insurance Co. lifted its stake in Allergan PLC. by 39.0% in the 3rd quarter. Sumitomo Life Insurance Co. now owns 15,122 shares of the company’s stock worth $3,099,000 after purchasing an additional 4,244 shares in the last quarter. Colony Group LLC lifted its stake in Allergan PLC. by 9.9% in the 2nd quarter. Colony Group LLC now owns 39,802 shares of the company’s stock worth $9,675,000 after purchasing an additional 3,577 shares in the last quarter. Finally, Palladium Partners LLC lifted its stake in Allergan PLC. by 1.7% in the 2nd quarter. Palladium Partners LLC now owns 31,161 shares of the company’s stock worth $7,575,000 after purchasing an additional 523 shares in the last quarter. Institutional investors and hedge funds own 81.21% of the company’s stock.
Shares of Allergan PLC. (AGN) traded up $2.20 on Tuesday, reaching $174.41. 2,600,200 shares of the company’s stock traded hands, compared to its average volume of 2,917,482. The stock has a market cap of $58,010.00, a PE ratio of 11.17, a P/E/G ratio of 1.09 and a beta of 1.12. The company has a quick ratio of 1.08, a current ratio of 1.18 and a debt-to-equity ratio of 0.40. Allergan PLC. has a fifty-two week low of $169.61 and a fifty-two week high of $256.80.
Allergan PLC. (NYSE:AGN) last announced its quarterly earnings results on Wednesday, November 1st. The company reported $4.15 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $4.06 by $0.09. The business had revenue of $4.03 billion during the quarter, compared to analysts’ expectations of $4.04 billion. Allergan PLC. had a negative net margin of 47.27% and a positive return on equity of 8.00%. The firm’s revenue for the quarter was up 11.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $3.32 EPS. analysts predict that Allergan PLC. will post 16.28 earnings per share for the current fiscal year.
Allergan PLC. announced that its Board of Directors has authorized a stock buyback plan on Monday, September 25th that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the company to buy up to 2.8% of its shares through open market purchases. Shares buyback plans are generally a sign that the company’s leadership believes its stock is undervalued.
The company also recently declared a quarterly dividend, which will be paid on Friday, December 15th. Shareholders of record on Friday, November 17th will be given a dividend of $0.70 per share. The ex-dividend date is Thursday, November 16th. This represents a $2.80 annualized dividend and a yield of 1.61%. Allergan PLC.’s payout ratio is currently -12.39%.
Several analysts have issued reports on the stock. UBS AG reiterated an “outperform” rating and issued a $275.00 target price on shares of Allergan PLC. in a research note on Wednesday, August 9th. BidaskClub lowered shares of Allergan PLC. from a “buy” rating to a “hold” rating in a report on Wednesday, August 9th. Wells Fargo & Company reissued an “outperform” rating and issued a $280.00 price target (up previously from $270.00) on shares of Allergan PLC. in a report on Wednesday, August 9th. Argus reissued a “buy” rating and issued a $280.00 price target on shares of Allergan PLC. in a report on Monday, August 14th. Finally, Cantor Fitzgerald reissued a “hold” rating on shares of Allergan PLC. in a report on Tuesday, August 22nd. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating and twelve have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $246.73.
Allergan PLC. Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.